These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18815926)

  • 1. Bladder cancer subtypes defined by genomic alterations.
    Knowles MA
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):116-30. PubMed ID: 18815926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium.
    Goebell PJ; Knowles MA
    Urol Oncol; 2010; 28(4):409-28. PubMed ID: 20610279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations associated with bladder cancer initiation and progression.
    Cordon-Cardo C
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):154-65. PubMed ID: 18815930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic epidemiology of bladder cancer: scaling up in the identification of low-penetrance genetic markers of bladder cancer risk and progression.
    Malats N
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):131-40. PubMed ID: 18815927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary bladder cancer.
    Kiemeney LA
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):110-5. PubMed ID: 18815925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study of bladder cancer gene and relevant molecular biology should be strengthened].
    Li CL; Han SJ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(12):793-4. PubMed ID: 17565855
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.
    Sugano K; Kakizoe T
    Nat Clin Pract Urol; 2006 Dec; 3(12):642-52. PubMed ID: 17149381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?
    Knowles MA
    Carcinogenesis; 2006 Mar; 27(3):361-73. PubMed ID: 16352616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers for detection, surveillance and prognostication of bladder cancer.
    Vrooman OP; Witjes JA
    Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular genetics of bladder cancer: pathways of development and progression.
    Knowles MA
    Cancer Surv; 1998; 31():49-76. PubMed ID: 15281317
    [No Abstract]   [Full Text] [Related]  

  • 11. Bladder cancer: modeling and translation.
    Rosenberg JE; Hahn WC
    Genes Dev; 2009 Mar; 23(6):655-9. PubMed ID: 19299556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
    van der Kwast TH; Bapat B
    Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder cancer: clinical and pathological profile.
    Lopez-Beltran A
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):95-109. PubMed ID: 18815924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder.
    Vázquez-Lavista LG; Lima G; Gabilondo F; Llorente L
    Urology; 2009 Aug; 74(2):414-8. PubMed ID: 19646633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
    Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
    van der Kwast TH
    Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic biomarkers in urothelial bladder cancer.
    Kim WJ; Kim YJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder cancer, a two phased disease?
    Höglund M
    Semin Cancer Biol; 2007 Jun; 17(3):225-32. PubMed ID: 16574430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.